Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.